The Library
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Tools
Tools
Tools
Barnett, A. H., Mackin, P., Chaudhury, I., Farooqi, A., Gadsby, Roger, Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., Taylor, D., Vora, J. and Jones, P. B. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology, Vol.21 (No.4). pp. 357-373. doi:10.1177/0269881107075509 ISSN 0269-8811.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1177/0269881107075509
Abstract
People with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and hypertension than the general population. This results in an increased incidence of cardiovascular disease (CVD) and reduced Life expectancy, over and above that imposed by their mental illness through suicide. Several levels of evidence from data linkage analyses to clinical trials demonstrate that treatment- related metabolic disturbances are commonplace in this patient group, and that the use of certain second-generation antipsychotics may compound the risk of developing the metabolic syndrome and CVD. In addition, smoking, poor diet, reduced physical activity and alcohol or drug abuse are prevalent in people with schizophrenia and contribute to the overall CVD risk. Management and minimization of metabolic risk factors are pertinent when providing optimal care to patients with schizophrenia. This review recommends a framework for the assessment, monitoring and management of patients with schizophrenia in the UK clinical setting.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RS Pharmacy and materia medica |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
| Journal or Publication Title: | Journal of Psychopharmacology | ||||
| Publisher: | Sage Publications Ltd. | ||||
| ISSN: | 0269-8811 | ||||
| Official Date: | June 2007 | ||||
| Dates: |
|
||||
| Volume: | Vol.21 | ||||
| Number: | No.4 | ||||
| Number of Pages: | 17 | ||||
| Page Range: | pp. 357-373 | ||||
| DOI: | 10.1177/0269881107075509 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
